Q-omics provides the consensus-scored CHRM3-AS2 profile across patient tissues and cancer cell-line models. CHRM3-AS2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CHRM3-AS2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, CHRM3-AS2 RNA expression shows 18,085 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CHRM3-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRM3-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRM3-AS2 survival associations across molecular data types. CHRM3-AS2 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRM3-AS2 RNA expression–survival associations across cancer types. High CHRM3-AS2 expression shows unfavorable associations in LGG, but favorable associations in HNSC, BRCA, SKCM, BLCA and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CHRM3-AS2 RNA expression.
This table summarizes CHRM3-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CHRM3-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRM3-AS2 shows lower tumor expression in KIRC, KIRP, KICH, COAD, THCA and BRCA. The KIRC box plot shows higher CHRM3-AS2 RNA expression in normal versus tumor tissue (log2 FC = −0.449, t-test p < 0.001).
This table shows molecular features associated with CHRM3-AS2 in patient tissues and cancer cell lines. In patient samples, CHRM3-AS2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
